Phosphodiesterase type 5 inhibitors and erectile dysfunction
Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management of ED. The PDE5-inhibitors have provided an e...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2010-06-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/1581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329722343817216 |
|---|---|
| author | Catherine Whittaker |
| author_facet | Catherine Whittaker |
| author_sort | Catherine Whittaker |
| collection | DOAJ |
| description | Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management of ED. The PDE5-inhibitors have provided an effective and patient-acceptable therapy for ED. They have had a huge impact on public awareness and understanding of this disease. This article provides an overview of erectile dysfunction and the pharmacology, efficacy, safety and optimal use of the PDE5-inhibitors. |
| format | Article |
| id | doaj-art-ca542e6ebe354b08b2ff48da879e890b |
| institution | Kabale University |
| issn | 2078-6190 2078-6204 |
| language | English |
| publishDate | 2010-06-01 |
| publisher | AOSIS |
| record_format | Article |
| series | South African Family Practice |
| spelling | doaj-art-ca542e6ebe354b08b2ff48da879e890b2025-08-20T03:47:10ZengAOSISSouth African Family Practice2078-61902078-62042010-06-0152310.1080/20786204.2010.108739721234Phosphodiesterase type 5 inhibitors and erectile dysfunctionCatherine Whittaker0Amayeza Information CentreErectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management of ED. The PDE5-inhibitors have provided an effective and patient-acceptable therapy for ED. They have had a huge impact on public awareness and understanding of this disease. This article provides an overview of erectile dysfunction and the pharmacology, efficacy, safety and optimal use of the PDE5-inhibitors.https://safpj.co.za/index.php/safpj/article/view/1581erectile dysfunctionpde5-inhibitorsvascular disease |
| spellingShingle | Catherine Whittaker Phosphodiesterase type 5 inhibitors and erectile dysfunction South African Family Practice erectile dysfunction pde5-inhibitors vascular disease |
| title | Phosphodiesterase type 5 inhibitors and erectile dysfunction |
| title_full | Phosphodiesterase type 5 inhibitors and erectile dysfunction |
| title_fullStr | Phosphodiesterase type 5 inhibitors and erectile dysfunction |
| title_full_unstemmed | Phosphodiesterase type 5 inhibitors and erectile dysfunction |
| title_short | Phosphodiesterase type 5 inhibitors and erectile dysfunction |
| title_sort | phosphodiesterase type 5 inhibitors and erectile dysfunction |
| topic | erectile dysfunction pde5-inhibitors vascular disease |
| url | https://safpj.co.za/index.php/safpj/article/view/1581 |
| work_keys_str_mv | AT catherinewhittaker phosphodiesterasetype5inhibitorsanderectiledysfunction |